Current Report Filing (8-k)
August 09 2019 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 6, 2019
Date of Report (Date of earliest event reported)
AEVI
GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of exchange on which registered
|
Common stock, par value $0.0001 per share
|
GNMX
|
Nasdaq Global Market
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 3.01.
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On August 6, 2019,
Aevi Genomic Medicine, Inc. (the “Company”), received written notice from the Listing Qualifications Staff (the “Staff”)
of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had not regained compliance with
the minimum bid price requirement and that it is not eligible for a second 180-day grace period to regain compliance because the
Company does not comply with the $10,000,000 stockholders’ equity initial listing requirement or equivalent standards for
The Nasdaq Global Market.
The Company will be
appealing the determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing
Rule 5800 Series. Such hearing request will stay the suspension of the Company’s common stock pending the Panel’s decision,
during which time the Company’s common stock will continue to be listed on Nasdaq and trade under the symbol “GNMX”.
Should the Company regain compliance with the minimum bid price requirement prior to the hearing it will request the hearing be
cancelled and that a written determination of compliance be provided to the Company.
The Company is diligently
working to evidence compliance with all applicable requirements for continued listing on The Nasdaq Global Market and
intends to submit a plan to that effect to the Panel as part of the hearing process; however, there can be no assurance
that the Panel will grant the Company’s request for continued listing on Nasdaq or that the Company will be able
to regain compliance with the applicable listing criteria within the period of time that may be granted by the Panel.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Michael F. Cola
|
|
|
|
Name: Michael F. Cola
|
|
|
|
Title: President and Chief Executive Officer
|
|
Date: August 9, 2019
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Apr 2023 to Apr 2024